Pharma News: VIVUS, Inc. (VVUS) Qsymia Patents, Arena Pharmaceuticals, Inc. (ARNA) Earnings, Amgen, Inc. (AMGN) Ending an Agreement

Edito’s Note:  VIVUS, Inc. (NASDAQ:VVUS),  Arena Pharmaceuticals, Inc. (NASDAQ:ARNA), Amgen, Inc. (NASDAQ:AMGN)

VIVUS, Inc. (NASDAQ:VVUS)VIVUS QSYMIA PATENTS: APPEARANCE OF ONGOING AND SYSTEMATIC INEQUITABLE CONDUCT BEFORE THE USPTO (World News Report)
Earlier today RFD IP Business Services (“RFD”) released a new report analyzing the likely inequitable conduct challenges to VIVUS, Inc. (NASDAQ:VVUS) and the patents that protect its approved drug, Qsymia(R) (fixed dose combinations of phentermine and topiramate). What is new in the Inequitable Conduct Report? The report exposes the tension between, on the one hand, admissions by Vivus attorneys at Mintz, Levin, Cohn, Ferris, Glovsky, and Popeo PC (“Mintz Levin”) that the company’s earliest Qsymia patents do not teach how to use low doses of topiramate (15 to 50 mg), while simultaneously trying to obtain claims from these early patents that cover doses of topiramate from 5 to 1000 mg.

News Buzz: Arena Pharmaceuticals, Inc. (NASDAQ:ARNA), Pandora Media Inc (NYSE:P) (SBWire)
Earnings of Arena Pharmaceuticals, Inc. (NASDAQ:ARNA) in the second quarter of 2013 at 17 cents per share were higher than the earnings in the previous year. The firm’s revenues of $68.9 million were 213% higher than the previous year for the same period thanks to $65 million milestone payment from partner Eisai for Belviq. The pharmaceutical firm had launched the obesity drug, Belviq in June 2013 and the drug has recorded sales of $1.3 million which is evident from the 12,500 prescriptions written for it until July 19. The firm also got $0.5 million milestone payment from Eisai submission of New Drug in Canada for Belviq.

Array says Amgen ends agreement, to cut 20 percent jobs (Reuters)
Array Biopharma said it would cut 20 percent of its workforce as  Amgen, Inc. (NASDAQ:AMGN) plans to end an agreement to develop and market Array’s drug to treat Type 2 diabetes. Array shares fell as much as 7 percent to $6.12 in trading after the bell. The company said it would record a one-time restructuring charge of $2.7 million in the first quarter of fiscal 2014. Array and  Amgen, Inc. (NASDAQ:AMGN) entered into the agreement in December 2009, under which Array received an upfront payment of $60 million and milestone payments of $8.5 million.

Amgen ‘neck and neck’ with competitors in race for new anti-cholesterol drugs approval (Med City News)
In one of the most closely-watched medical races of all time, Amgen and rival pharmaceutical companies are chasing approval for new anti-cholesterol drugs that have the potential to be blockbusters. Cardiologists see them as the single most promising class of drugs currently in development, said Dr. Steven Nissen, the department chair of cardiovascular medicine at the Cleveland Clinic. For its new cholesterol-fighting drug, AMG 145, Thousand Oaks-based Amgen expects to have data from its pre-marketing clinical trial period available in early 2014.

2 Biotechs Aim To Capitalize On The Treatment Of Melanoma (Seeking Alpha)
Data from key trials of experimental treatments for melanoma brings good news for those affected by this deadly form of cancer. Following the disappointment from Vical’s (VICL) failed Phase 3 study, the development of melanoma treatments offer investors a solid opportunity with two different stocks.

blog comments powered by Disqus
Insider Monkey Headlines
Insider Monkey Small Cap Strategy
Insider Monkey Small Cap Strategy

Insider Monkey beat the market by 52 percentage points in 24 months Click to see monthly returns in table format!

Lists

The Top 10 States With Fastest Internet Speeds

10 Best Places to Visit in USA in August

Top 10 Cities to Visit Before You Die

Top 10 Genetically Modified Food In the US

15 Highest Grossing Movies Opening Weekend

5 Best Poker Books For Beginners

10 Strategies Hedge Funds Use to Make Huge Returns

Top 10 Fast Food Franchises to Buy

10 Best Places to Visit in Canada

Best Summer Jobs for Teachers

10 Youngest Hedge Fund Billionaires

Top 10 One Hit Wonders of the 90s

Fastest Growing Cities In America

Top 10 U.S. Cities for Freelancers

Top 9 Most Popular Free iPhone Apps

Top 10 Least Expensive Private Business Schools in the US

Top 15 Most Expensive Countries in the World – 2014

Top Businesses to Invest In

Top 5 Things You Might Be Doing Wrong With Your Business

Top 5 Strategic Technology Trends in 2014

Top Rags to Riches Stories

Parenting Behavior That Promotes Future Leaders

Top 5 Mistakes Made by Small Businesses

Top 5 Most Common and Potentially Devastating Financial Blunders

Top 5 Highest Paying Jobs for Web Designers

Top 6 Most Respected Professions that Also Pay Well

Top 5 Pitfalls Investors Should Avoid

Top 6 Lawyers and Policy Makers Under 30

Top 6 New Year’s Resolutions for Entrepreneurs

Top 7 Locations to Check in on Facebook

Top 5 Mistakes made by Rookie eBay Sellers

Top 7 eBook Publishers in 2013

Top 6 Health Industry Trends in 2014

5 Lessons for Entrepreneurs from Seth Godin

Top 5 Success Tips from Jordan Belfort – the Wolf of Wall Street

Best Master’s in Finance Degree Programs

Top 6 Earning Celebrities Over 50

The most expensive sports to play

Top 7 Earning Celebrities Under 25

Best 7 Online Courses to Take: Free Finance MOOCs

Top 6 Bad Habits that Promote Failure

20 Most Valuable Soccer Teams in the World in 2013

12 Most Expensive Countries for Foreign Students

Top 30 Most Influential Women in the World

Top 20 Most Expensive New Year Eve Shows

Top 5 Best Vocational Careers

Top 10 Jobs for 2014 by Salary Gain (Predictions)

Top 5 Digital Trends for 2014

Top 6 Things You Can Do To Increase Your Productivity

Top 9 Trending Smartphones in 2013

Subscribe

Enter your email:

Delivered by FeedBurner

X

Thanks! An email with instructions is sent to !

Your email already exists in our database. Click here to go to your subscriptions

Insider Monkey returned 47.6% in its first year! Wondering How?

Download a complete edition of our newsletter for free!